Fluticasone propionate intranasal - OptiNose

Drug Profile

Fluticasone propionate intranasal - OptiNose

Alternative Names: FLU-EDS; OPN-375; Opt-FP; OPTINOSE; OptiNose fluticasone propionate; XHANCE

Latest Information Update: 23 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OptiNose AS
  • Developer OptiNose
  • Class Analgesics; Androstadienes; Anti-inflammatories; Antiallergics; Antiasthmatics; Glucocorticoids; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Lipocortin synthesis agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Nasal polyps
  • Phase III Sinusitis
  • No development reported Asthma

Most Recent Events

  • 13 Mar 2018 Optinose plans a phase IIIb trial in Chronic sinusitis in fourth quarter of 2018
  • 02 Mar 2018 Pooled efficacy data from the phase III EXHANCE-3 and EXHANCE-12 trials in Sinusitis presented at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2018)
  • 09 Jan 2018 OptiNose's Fluticasone propionate intranasal is planned to be launched in USA in the second quarter of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top